Announced details
Cancer drug research and development, genomic research, genomic medicine, clinical testing, inbound medical services, and personalized cancer medicine
Global cancer incidence is projected to increase from approximately 19.3 million cases in 2020 to approximately 28.4 million in 2040, an increase of approximately 47%. Global spending on cancer medicines is projected to increase from $223 billion in 2023 to $409 billion in 2028.
More than 1,000 clinical specimens have been used to identify cancer-specific genes. The number of patients is 20 to 80 per cancer type.
CPM has entered into a joint research agreement with the Human Genome Center, the Institute of Medical Science, the University of Tokyo. CPM has a business partnership with 株式会社JTB concerning inbound medical services. Shionogi & Co.,Ltd. is the licensee for multiple investigational drugs. The funds identified in the materials are the allottees of the new shares and stock acquisition rights.
Professor Seiya Imoto (井元清哉) of the Department of Health and Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, and 株式会社JTB have expertise and a track record in medical coordination. Information on the other counterparties is not disclosed.
CAP accreditation
ISO/IEC 27001:2022
College of American Pathologists（CAP）
G-CERTI Co., Ltd. (IAS-accredited)
CAP registration number: 2237188. ISO/IEC 27001:2022 certification number: GIJP-1972-IC; initial certification date: 5 November 2025; IAS registration number: MSCB-113. The expiration date is not disclosed.
The materials describe opportunities for business partnerships, securing stable revenue, and enhancing corporate value as effects of the business model, but the specific impact on financial results in this material is not disclosed.
The company does not address Contract Value / Offering price.
GLOBOCAN 2020, Sung et al., CA Cancer J Clin.
FY2016 Grants-in-Aid for Scientific Research (KAKENHI), Category B (General), “Causes and Contributions of Cancer in the Japanese Population: Latest Estimates and Future Projections”
National Cancer Center, Cancer Information Service, “Cancer Registry and Statistics”
IQVIA Institute, Global Oncology Trends 2024: Outlook to 2028
IQVIA Institute, Global Oncology Trends 2019
| Item | Details |
|---|---|
| Names of Products / Services Covered | Research and development of OTS pharmaceuticals, CPM genetic analysis services, Contract long-read sequencing analysis services, Cancer gene panel testing, Neoantigen therapy, Liquid Biopsy |
| Counterparty | Professor Seiya Imoto (井元清哉), Department of Health and Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, JTB Co., Ltd., Shionogi & Co.,Ltd., Long Corridor Alpha Opportunities Master Fund, MAP246 Segregated Portfolio, BEMAP Master Fund Ltd. |
| Counterparty overview | Professor Seiya Imoto (井元清哉) of the Department of Health and Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, and 株式会社JTB have expertise and a track record in medical coordination. Information on the other counterparties is not disclosed. |
| Relationship with the Company | CPM has entered into a joint research agreement with the Human Genome Center, the Institute of Medical Science, the University of Tokyo. CPM has a business partnership with 株式会社JTB concerning inbound medical services. Shionogi & Co.,Ltd. is the licensee for multiple investigational drugs. The funds identified in the materials are the allottees of the new shares and stock acquisition rights. |
| Contract Date | Joint research agreement with the Human Genome Center, the Institute of Medical Science, the University of Tokyo: October 2025. Business partnership with 株式会社JTB: October 2025. |
| Launch date | Contract long-read sequencing analysis services: launched in November 2025 (track record) |
| Applicable area | Cancer drug research and development, genomic research, genomic medicine, clinical testing, inbound medical services, and personalized cancer medicine |
| Award/certification name | CAP accreditation, ISO/IEC 27001:2022 |
| Awarding / certifying body | College of American Pathologists（CAP）, G-CERTI Co., Ltd. (IAS-accredited) |
| Registration number and expiry date | CAP registration number: 2237188. ISO/IEC 27001:2022 certification number: GIJP-1972-IC; initial certification date: 5 November 2025; IAS registration number: MSCB-113. The expiration date is not disclosed. |
| Quantitative Effects | Global cancer incidence is projected to increase from approximately 19.3 million cases in 2020 to approximately 28.4 million in 2040, an increase of approximately 47%. Global spending on cancer medicines is projected to increase from $223 billion in 2023 to $409 billion in 2028. |
| Usage history | More than 1,000 clinical specimens have been used to identify cancer-specific genes. The number of patients is 20 to 80 per cancer type. |
| Impact on Business Performance | The materials describe opportunities for business partnerships, securing stable revenue, and enhancing corporate value as effects of the business model, but the specific impact on financial results in this material is not disclosed. |
| Source | GLOBOCAN 2020, Sung et al., CA Cancer J Clin., FY2016 Grants-in-Aid for Scientific Research (KAKENHI), Category B (General), “Causes and Contributions of Cancer in the Japanese Population: Latest Estimates and Future Projections”, National Cancer Center, Cancer Information Service, “Cancer Registry and Statistics”, IQVIA Institute, Global Oncology Trends 2024: Outlook to 2028, IQVIA Institute, Global Oncology Trends 2019 |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide information to investors.